The Pennsylvania Biotechnology Center partnership offers biotech residents flexible, plug & play lab and research space within a...
ILC Doveror specializing in innovative single-use solutions for biotherapeutics and pharmaceutical processing, announced the launch of Water for Injection (WFI) for the biotherapeutics market.
Zeus, the global leader in advanced polymer solutions, today announced a multi-million dollar investment to expand its catheter manufacturing capacity worldwide
Arranta Bio (“Arranta”), a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, today announced plans to establish contract manufacturing capacity for messenger RNA (mRNA) vaccines.
Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories Inc. today announced their partnership to launch a new network of mobile CGT manufacturing facilities.
Precision Coating, a leading medical coatings service provider to interventional, orthopedic, and advanced surgical markets, is pleased to announce a merger with N2 Biomedical, a Bedford, MA-based company.
The Annual ISPE Boston Product Show is the premier one-day biopharmaceutical show in the Northeast and the flagship event of the ISPE Boston Area Chapter.
Olympus announced today the results of a pilot study showing the safety and effectiveness of the ViziShot 2 FLEX 19 G EBUS-TBNA Needle in gathering tissue samples critical to guiding treatment of non-small cell lung cancer (NSCLC).
Boston Scientific completes the acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based medical solutions, from an affiliate of Baring Private Equity Asia (BPEA).
MicroCNX connectors are a critically important option for a range of bioprocessing, cell therapy and gene therapy workflows,.”Until now, cumbersome tube welding has been the only way to make sterile closed connections of very small-bore tubing. The MicroCNX connector represents a huge innovation for the industry.
Proposed acquisition of Trillium strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies
Signature Biologics, LLC., today announced their expanded operations footprint to include a new 36,000 sq ft facility in Irving, TX. This newly constructed space mirrors Signature Biologics’ transparency in doing business with open floor plan and floor-to-ceiling views into its fully equipped manufacturing and R&D laboratory spaces.